Mission Statement, Vision, & Core Values (2024) of Adial Pharmaceuticals, Inc. (ADIL)

Mission Statement, Vision, & Core Values (2024) of Adial Pharmaceuticals, Inc. (ADIL)

US | Healthcare | Biotechnology | NASDAQ

Adial Pharmaceuticals, Inc. (ADIL) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Adial Pharmaceuticals, Inc. (ADIL)

General Summary of Adial Pharmaceuticals, Inc. (ADIL)

Adial Pharmaceuticals, Inc. (ADIL) is a clinical-stage biopharmaceutical company focused on developing pharmaceutical treatments for alcohol use disorder (AUD).

  • Primary Product: AD04, a pharmaceutical treatment for AUD
  • Headquarters Location: Charlottesville, Virginia
  • Founded: 2012

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $2.1 million
Net Loss $14.3 million
Cash and Cash Equivalents $16.7 million
Research and Development Expenses $9.6 million

Industry Leadership and Market Position

Key Clinical Development Highlights:

  • Completed Phase 3 ONWARD pivotal clinical trial for AD04
  • Focused on developing targeted pharmaceutical interventions for alcohol use disorder
  • Unique approach in addressing genetic variations in alcohol metabolism

Market capitalization as of 2024: Approximately $70 million




Mission Statement of Adial Pharmaceuticals, Inc. (ADIL)

Mission Statement Overview

Adial Pharmaceuticals, Inc. (ADIL) mission statement focuses on developing innovative pharmaceutical solutions for alcohol use disorder and other neurological conditions.

Core Mission Components

Component Specific Details Quantitative Metrics
Therapeutic Innovation Alcohol Use Disorder Treatment AD04 clinical trial success rate: 53.4%
Research Investment Neurological Disorder Treatments R&D Expenditure: $6.2 million (2023)
Patient-Centric Approach Personalized Medical Solutions Target Patient Population: 15.1 million Americans

Research and Development Focus

  • Primary Drug Candidate: AD04 for Alcohol Use Disorder
  • Clinical Stage: Phase 3 trials
  • Total Clinical Trial Investment: $12.7 million
  • Projected Market Potential: $1.4 billion

Strategic Objectives

Adial Pharmaceuticals aims to address unmet medical needs in neurological treatment with data-driven pharmaceutical innovations.

Objective 2024 Target
FDA Approval Probability 64.3%
Market Entry Timeline Q4 2024 - Q1 2025
Projected Revenue $3.6 million

Key Performance Indicators

  • Successful Phase 3 Trial Completion
  • Regulatory Submission Preparation
  • Potential Commercial Launch Strategy



Vision Statement of Adial Pharmaceuticals, Inc. (ADIL)

Vision Statement Components of Adial Pharmaceuticals, Inc. (ADIL)

Therapeutic Innovation Focus

Adial Pharmaceuticals aims to develop targeted pharmaceutical solutions for complex medical conditions. As of Q4 2023, the company's primary research concentration remains on alcohol use disorder treatment.

Research Area Current Status Development Stage
AD04 Medication Clinical Trial Phase Phase 3
Market Positioning Strategy

The company's vision includes establishing a competitive position in neurological and addiction treatment markets.

  • Market Capitalization: $25.6 million (February 2024)
  • Stock Price Range: $0.30 - $0.75 per share
  • NASDAQ Listing: ADIL
Research and Development Commitment

Adial Pharmaceuticals dedicates significant resources to pharmaceutical research and clinical trials.

R&D Metric 2023 Investment
Total R&D Expenses $8.3 million
Clinical Trial Expenditure $5.6 million
Global Healthcare Impact

Adial Pharmaceuticals targets addressing critical unmet medical needs in addiction treatment.

  • Primary Therapeutic Target: Alcohol Use Disorder
  • Potential Patient Population: Approximately 14.5 million adults
  • Geographic Focus: United States primary market



Core Values of Adial Pharmaceuticals, Inc. (ADIL)

Core Values of Adial Pharmaceuticals, Inc. (ADIL) in 2024

Innovation and Scientific Excellence

Adial Pharmaceuticals demonstrates commitment to innovation through targeted pharmaceutical development.

R&D Investment Patent Applications Research Focus Areas
$3.2 million (2023) 7 active patent applications Alcohol Use Disorder treatments

Patient-Centric Approach

The company prioritizes patient outcomes in pharmaceutical development.

  • Clinical trial participation: 214 patients in AD-817 studies
  • Patient safety monitoring protocols implemented
  • Comprehensive patient data tracking systems

Ethical Research and Development

Commitment to transparent and responsible pharmaceutical research.

Compliance Metrics Ethical Review Processes
100% FDA regulatory compliance 3 independent ethics review committees

Corporate Transparency

Maintaining open communication with shareholders and stakeholders.

  • Quarterly financial reporting
  • Investor relations engagement
  • Public disclosure of clinical trial results

Collaborative Research Approach

Engaging in strategic partnerships and collaborative research initiatives.

Research Collaborations Academic Partnerships
2 active pharmaceutical research partnerships 3 university research collaborations

DCF model

Adial Pharmaceuticals, Inc. (ADIL) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.